These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9443667)

  • 1. HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
    Uchida H; Maeda Y; Mitsuya H
    Antiviral Res; 1997 Nov; 36(2):107-13. PubMed ID: 9443667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.
    Nagy K; Young M; Baboonian C; Merson J; Whittle P; Oroszlan S
    J Virol; 1994 Feb; 68(2):757-65. PubMed ID: 8289379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
    Perno CF; Newcomb FM; Davis DA; Aquaro S; Humphrey RW; Caliò R; Yarchoan R
    J Infect Dis; 1998 Aug; 178(2):413-22. PubMed ID: 9697721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy.
    Piketty C; Race E; Castiel P; Belec L; Peytavin G; Si-Mohamed A; Gonzalez-Canali G; Weiss L; Clavel F; Kazatchkine MD
    AIDS; 1999 Jul; 13(11):F71-7. PubMed ID: 10449277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
    Côté HC; Brumme ZL; Harrigan PR
    J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro.
    Panther LA; Coombs RW; Aung SA; dela Rosa C; Gretch D; Corey L
    J Med Virol; 1999 Jun; 58(2):165-73. PubMed ID: 10335865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.
    Karmochkine M; Si Mohamed A; Piketty C; Ginsburg C; Raguin G; Schneider-Fauveau V; Gutmann L; Kazatchkine MD; Belec L
    Antiviral Res; 2000 Sep; 47(3):179-88. PubMed ID: 10974370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.
    Valer L; de Mendoza C; Soriano V
    J Med Virol; 2005 Dec; 77(4):460-4. PubMed ID: 16254964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
    Velazquez-Campoy A; Vega S; Freire E
    Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibilities of simian immunodeficiency virus to protease inhibitors.
    Giuffre AC; Higgins J; Buckheit RW; North TW
    Antimicrob Agents Chemother; 2003 May; 47(5):1756-9. PubMed ID: 12709355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removal of human immunodeficiency virus type 1 (HIV-1) protease inhibitors from preparations of immature HIV-1 virions does not result in an increase in infectivity or the appearance of mature morphology.
    Humphrey RW; Ohagen A; Davis DA; Fukazawa T; Hayashi H; Höglund S; Mitsuya H; Yarchoan R
    Antimicrob Agents Chemother; 1997 May; 41(5):1017-23. PubMed ID: 9145862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system.
    Zhang L; Gorset W; Washington CB; Blaschke TF; Kroetz DL; Giacomini KM
    Drug Metab Dispos; 2000 Mar; 28(3):329-34. PubMed ID: 10681378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells.
    Goto T; Nakano T; Kohno T; Morimatsu S; Morita C; Hong W; Kiso Y; Nakai M; Sano K
    J Med Virol; 2001 Mar; 63(3):203-9. PubMed ID: 11170058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 protease inhibitors. A review for clinicians.
    Deeks SG; Smith M; Holodniy M; Kahn JO
    JAMA; 1997 Jan; 277(2):145-53. PubMed ID: 8990341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.
    Yusa K; Kavlick MF; Kosalaraksa P; Mitsuya H
    Antiviral Res; 1997 Dec; 36(3):179-89. PubMed ID: 9477118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.
    Pellegrin I; Breilh D; Birac V; Deneyrolles M; Mercié P; Trylesinski A; Neau D; Saux MC; Fleury HJ; Pellegrin JL
    Ther Drug Monit; 2001 Aug; 23(4):332-40. PubMed ID: 11477313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
    Mammano F; Trouplin V; Zennou V; Clavel F
    J Virol; 2000 Sep; 74(18):8524-31. PubMed ID: 10954553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
    Taylor DL; Ahmed PS; Tyms AS; Wood LJ; Kelly LA; Chambers P; Clarke J; Bedard J; Bowlin TL; Rando RF
    Antivir Chem Chemother; 2000 Jul; 11(4):291-301. PubMed ID: 10950391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV protease inhibitors.
    Carr A; Cooper DA
    AIDS; 1996; 10 Suppl A():S151-7. PubMed ID: 8883623
    [No Abstract]   [Full Text] [Related]  

  • 20. Dissimilar attenuation of Candida albicans virulence properties by human immunodeficiency virus type 1 protease inhibitors.
    Gruber A; Berlit J; Speth C; Lass-Flörl C; Kofler G; Nagl M; Borg-von Zepelin M; Dierich MP; Würzner R
    Immunobiology; 1999 Sep; 201(1):133-44. PubMed ID: 10532286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.